@

Meet us

NextMeeting

> english version Imprint

 

Impressum

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Telefon: +49 6221 4294830
Telefax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH wird vertreten durch: Geschäftsführer Dr. Christoph Schröder

 

Registergericht: Amtsgericht Mannheim
Handelsregister
Registernummer: HRB716969

Umsatzsteuer-Identifikationsnummer gemäß § 27a Umsatzsteuergesetz: DE289272460

 

Urheberrecht

Alle Inhalte der Internetpräsenz der Sciomics GmbH sind urheberrechtlich geschützt. Dies gilt für Texte wie auch Fotos, Grafiken sowie PDF-Dokumente.
Jede Vervielfältigung oder Verbreitung dieses Internetangebotes oder auch von Inhalten, Auszügen, Dateien oder anderen Teilen davon, zum Beispiel zum Nachdruck, zur Kopie in andere Internetseiten oder zur Weitergabe in elektronischer Form, bedarf der schriftlichen Genehmigung der Sciomics GmbH.

 

Haftung

Trotz sorgfältiger inhaltlicher Kontrolle übernehmen wir keine Haftung für die Inhalte externer Links. Für den Inhalt der verlinkten Seiten sind ausschließlich deren Betreiber verantwortlich.

 

 

 

Imprint

 

Sciomics GmbH
Karl-Landsteiner-Str. 6
69151 Neckargemünd
Phone: +49 6221 4294830
Fax: +49 6221 4294834
E-Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Internet: http://www.sciomics.de
Sciomics GmbH is represented by: Geschäftsführer Dr. Christoph Schröder

 

Register jurisdiction: Amtsgericht Mannheim
Commercial Register
Registration number: HRB716969

Umsatzsteuer-Identifikationsnummer (VAT identification number) according to §27a of the Umsatzsteuergesetz (UStG, Sales Tax Law): DE289272460

 

Copyright

The layout, texts, text fragments and graphics used and any other contents on the homepage protected by copyright law. All rights reserved.

 

Liability

Links have been proved during setup. Since information on the WWW is subject of current change Sciomics accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.
This disclaimer is not intended to contravene any requirements laid down in applicable national law nor to exclude liability for matters which may not be excluded under that law.


 

 

 

 

COVID-19 related activities and services

covid 19 portfolio web

News

New article | Prevention of Cyclosp.-A mediated anemia and peritubular loss

| June 2022 | In a study by Robert Labes et al. insights in prevention of cyclosporine mediated anemia and peritubular capillary loss were identified.

Labes, R. et al. Daprodust. prevents cyclosp.-A mediated anemia and peritubular capillary loss. Kidney International 2022 in press.
New article | The Lifestyle Modifications Affect the Endometrial Proteome

| June 2022 | In a study by D. Abdulkhalikova et al. Endometrial Proteome changes werde identified impacted by Lifestyle modification in woman with Polycystic Ovarian Syndrome and Obesity.

Abdulkhalikova, DR. et al. The Lifestyle Modifications and Endometrial Proteome Changes of Women With Polycystic Ovary Syndrome and Obesity. Front. Endocrinol. 2022 in press.
New article | Cycle-dependent biomarkers in endometriosis

| May 2022 | In a study by Maja Pušić et al. Cycle-dependent plasma protein biomarkers for peritoneal endometriosis were identified by our scioDiscover platform.

Pušić, M. et al. Antibody Arrays Identified Cycle-Dependent Plasma Biomarker Candidates of Peritoneal Endometriosis. J. Pers. Med. 2022, 12, 852.
New article | Co-Expression of microRNAs and Proteins in Alzheimer’s Disease

| Jan 2022 | In a study by Valentina di Pietro at Birmingham University our scioDoiscover platform was used to analyse the co-expression of proteins and microRNAs in the brains of Alzheimer's disease patients.

Watson, C. N. et al. Co-Expression Analysis of microRNAs and Proteins in Brain of Alzheimer’s Disease Patients. Cells 11, 163 (2022).
New article | ETV6 levels predict outcome in DLBCL

| Jan 2022 | Erich Piovan and collegues at University of Padua collaborated with Sciomics to study specific biomarkers in FFPE tissue samples of DLBCL patients by custom antibody microarrays.

Marino, D. et al. High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients. Cancers 14, (2022).

Testimonials

Dr. Bettina Grötsch

Department of Medicine 3 - Rheumatology and Immunology, University Clinics Erlangen, Erlangen, Germany

"Our lab is working with human osteoclast that were isolated and differentiated from human peripheral blood. Therefore, we were quite limited in cell numbers and protein content for our planned Phosphoprotein analyses. Nonetheless, Sciomics and especially Camille Lowy helped us a lot to test and improve our protein isolation techniques to achieve some interesting phosphoproteome data in human osteoclasts. We were really impressed by the detailed data report and their willingness to discuss and reanalyze the data repeatedly until we got the best results out of our measurements. Even several month after their first report, we could ask for help and suggestions with an immediate reply.  The phosphoproteome analyses completed our preliminary project data and are now published in Frontiers Immunology.  Altogether, we were very happy with the service of Sciomics and special thanks to Camille Lowy and Christoph Schröder who guided us through the whole process."

Product: scioPhospho
Publication: Grötsch B. et al. 2022 Front. Immunol. 13:958974 

Alenka Djarmila Behsen, PhD candidate

Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

"The process of working with Ronny and his colleagues at Sciomics has been very easy and efficient. Response time is very quick and they are always available for meetings when you have more questions. Would definitely recommend working with Sciomics."

Product: scioCD

 

Tweets

BACK_TO_TOP